Research
Hormonal
The reduction in sympathetic activity (norepinephrine spillover) following weight loss is independently associated with the reduction in plasma leptin concentrations, suggesting leptin mediates this effect.
Weight loss improves heart health partly by lowering leptin levels, which in turn calms overactive sympathetic nerve signals. This suggests that managing leptin sensitivity is crucial for cardiovascular health in metabolic syndrome.
GoodQualifiesHIGH confidence
The change in the norepinephrine spillover rate correlated positively and independently with the change in plasma leptin concentration (r (cid:2) 0.49; P (cid:2) 0.03).
Why this rating
Strong correlation with independent regression analysis, but observational within the intervention context.
Source
Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome
Nora E. Straznicky et al. · The Journal of Clinical Endocrinology & Metabolism · 2005
DOI 10.1210/jc.2005-0961
clinical_trial · n=23Cited 227×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary weight loss via a hypocaloric DASH-based diet significantly reduces sympathetic nervous system (SNS) activity (norepinephrine spillover and muscle sympathetic nerve activity) and improves cardiac baroreflex sensitivity in subjects with metabolic syndrome.Good
- Insulin-resistant subjects experience a significant reduction in whole-body norepinephrine spillover after weight loss, whereas insulin-sensitive subjects do not, despite similar weight loss amounts.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →